We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test for Cardiac Protein Diagnoses Heart Attack

By LabMedica International staff writers
Posted on 17 Nov 2011
Print article
A novel blood test for a cardiac biomarker has been used to determine whether a patient has had a heart attack.

The test measures a large protein known as cardiac myosin binding protein-C (cMyBP-C), which is released into the blood following a cardiac event.

Scientists at Loyola University Chicago (Maywood, IL, USA) quantified plasma levels of cMyBP-C by a sandwich enzyme-linked immunosorbent assay (ELISA) using capture monoclonal anti-cMyBP-C, E7 and a detection rabbit polyclonal antibody anti-cMyBP-CC0–C1. Plasma cardiac troponin (cTnI) levels were also measured by a commercial sandwich ELISA. To determine the sensitivity of the sandwich ELISA for cMyBP-C, the investigators defined the limit of detection values and quantification for lower and upper limits. The values of lower limit of quantification and upper limit of quantification were 0.02 ng/ml and 2,053 ng/ml, respectively.

Plasma samples were collected from 16 myocardial infarction) MI) patients and 11 normal healthy controls. Importantly, cMyBP-C and cTnI levels in the plasma samples of healthy controls were very low, 0.95 ± 0.34 ng/mL and 0.238 ± 0.07 ng/mL, respectively. Strikingly, the concentration of cMyBP-C in the plasma of MI patients was significantly increased to 227 ± 50 ng/mL, compared to controls and greater than plasma cTnI levels at 30 ± 9 ng/mL. The anti-cMyBP-C, E7 monoclonal antibody used in this study is a product Santa Cruz Biotechnology (Santa Cruz, CA, USA). The human cardiac troponin assay was produced by Calbiotech (San Diego, CA, USA).


Sakthivel Sadayappan, PhD, senior author of the study said, "This potentially could become the basis for a new test, used in conjunction with other blood tests, to help diagnose heart attacks. This is the beginning. A lot of additional studies will be necessary to establish cMyBP-C as a true biomarker for heart attacks." The authors concluded that future studies would determine the time course of release, peak concentrations, and half-life in the circulatory system. The study was available online since September 19, 2011, in the Journal of Molecular and Cellular Cardiology.

Related Links:
Loyola University Chicago
Santa Cruz Biotechnology
Calbiotech


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.